Browse by Day Archive

Scholar Rock says its first muscle-targeted SMA therapy will cost about $310,000 annually

09/14/2026 6:38am
Scholar Rock on Monday said the net annual cost of its newly ​approved spinal muscular atrophy treatment will be about $310,000 for a typical patient, after the drug became the first ‌therapy approved to directly target muscle loss associated with the rare genetic disorder.

BioNTech says lung cancer drug candidate prolonged lives in trial

09/14/2026 2:06am
BioNTech ​said on Monday that a late-stage ‌trial showed its drug ⁠candidate gotistobart ​led ⁠to a clinically ‌meaningful overall ‌survival benefit in ⁠a ⁠certain form of lung cancer compared with standard treatment.